US Patent

US8598196 — Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy

Method of Use · Assigned to Medicis Pharmaceutical Corp · Expires 2029-08-18 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating dermatological disorders and inducing interferon biosynthesis using shorter durations of imiquimod therapy.

USPTO Abstract

Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-172 — Aldara

Patent Metadata

Patent number
US8598196
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Medicis Pharmaceutical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.